PRICE INDEXES OF MENTAL HEALTH TREATMENT

价格指数是最基本的经济统计数据之一。 他们试图总结购买或生产一套特定的商品和服务以达到一定水平的福祉的成本或价格。 在保健领域，价格指数被概念化为获得某种结果或保健质量的成本。 因此，价格指数直接关系到我们如何看待卫生经济的表现。这项研究的主要目标是制定精神卫生系统的价格指数措施，利用行政数据，结合临床研究和临床专业知识的学习。 我们的目标是衡量与预期结果水平相关的治疗支出（或价格）。 该研究建立在一系列试点研究的基础上，这些研究探讨了构建重度抑郁症急性期治疗价格指数的可行性。在这里描述的研究中，我们建议将试点研究扩展到：1）更广泛的抑郁症治疗（急性加持续阶段治疗），2）精神分裂症的治疗和3）更广泛的环境，如具有有限心理健康福利的HMO和州医疗补助计划。 这项工作的长期目标是制定措施，帮助政策制定者和倡导者更好地解释心理健康支出数据，并提高利用行政数据和现有临床研究评估服务于大量人群的方案绩效的能力。 我们将利用三个大型数据集，包括一个大型的私人保险人口，从428，000名注册者八年，366，000名HMO和POS注册者四年到超过300万名医疗补助注册者四年。 为了评估结果，我们将使用临床文献沿着以及三个临床医生-研究人员专家小组来评估特定消费者和治疗组合的预期结果。

Price indexes are among the most fundamental of economic statistics. They seek to summarize the cost or price of purchasing or producing a particular set of goods and services to attain a certain level of well being. In the health care area price indexes have been conceptualized as the cost of obtaining a certain outcome or quality of care. As such a price index bears directly on how we view the performance of the health economy. The principal goal of this research is to develop price index measures for mental health systems that makes use of administrative data, incorporating learning from clinical research and clinical expertise. Our aim is to measure spending (or the price) of treatments associated with an expected level of outcome. The research builds on a series of pilot studies that examined the feasibility of constructing price indexes for the acute phase treatment of major depression. In the research described here, we propose to extend pilot research to: 1) a broader view of treatment for depression (acute plus continuation phase treatment), 2) treatment of schizophrenia and 3) a wider range of settings such as an HMOs with limited mental health benefits and a state Medicaid program. The long term aim of this work is to develop measures that will help policy makers and advocates better interpret data on mental health spending and enhance the ability to assess the performance of programs serving large populations using administrative data and existing clinical research. We will draw upon three large data sets including a large privately insured population from 428,000 enrollees for eight years, 366,000 HMO and POS enrollees for four years to over 3 million Medicaid enrollees over four years. To assess outcomes we will use clinical literature along with three expert panels of clinician-researchers to rate expected outcomes for specific combinations of consumers and treatments.